5-HTP, Sleep and Mood: What the Studies Really Show

In people who sleep poorly, yes, in the most solid trial we have: 100 mg per day for 12 weeks improved the overall sleep score of poor sleepers in a group of 30 adults averaging 66 years old, with an increase in blood serotonin and microbiota diversity. In good sleepers from the same trial, nothing changed. So the effect depends on the starting point.

Because it feeds a chain: tryptophan, 5-HTP, serotonin, then melatonin. Melatonin is produced at night from serotonin by the pineal gland, and serotonin itself is produced from 5-HTP. Providing 5-HTP amounts to supplying the raw material for the sleep hormone, entering the chain after its slowest step.

They are not the same tools. Melatonin is the hormone itself: it gives a time signal and acts mainly on sleep onset time and jet lag. 5-HTP is upstream: it supplies the raw material for serotonin, then melatonin, and acts more broadly on mood and satiety. In trials, 5-HTP was evaluated over weeks, melatonin often over nights.

This is an effect reported by some users and consistent with measurements: in 18 Parkinson's patients, 50 mg per day increased the proportion of REM sleep, the dream phase, without increasing episodes of REM sleep behavior disorder. More abundant REM sleep can make dreams more memorable. If this is bothersome, reduce the dose or take it earlier.

A 2020 meta-analysis covering 13 studies found a remission rate of 65% and a large effect size, while rating study quality as low. A double-blind randomized trial in 60 first-episode depressive patients measured a 73% response to 5-HTP versus 80% to fluoxetine at 8 weeks, with no significant difference, and visible effects from the second week onward. The signal is real, the level of evidence moderate.

In the trial versus fluoxetine, the difference was measurable by the second week and continued to improve through week eight. In the senior trial, the geriatric depression score improved by week eight. The practical benchmark is therefore to allow at least four weeks before assessing, and eight weeks to decide whether to continue.

The reference trial in seniors used 100 mg per day for 12 weeks. In Parkinson's patients, 50 mg was sufficient to modify sleep architecture. One capsule of griffonia extract at 30% dosed at 300 mg provides 90 mg of 5-HTP, which places one capsule in the evening within the studied range.

Thirty to sixty minutes before bedtime. The half-life of 5-HTP is 2 to 7 hours, which covers the early part of the night, and conversion to melatonin occurs in darkness. It can be taken with or without food, as its absorption does not depend on a transporter competing with amino acids from meals.

Spread throughout the day rather than all at once, given its short half-life. Two doses, morning and early afternoon, best replicate the study protocols. If sleep is also a concern, shifting the second dose toward evening allows you to address both at the same time.

Yes, their mechanisms are distinct and neither is serotonergic. Glycine acts on thermoregulation and subjective sleep quality at 3 g before bedtime, magnesium on neuromuscular relaxation and the nervous system. They do not accumulate risk with 5-HTP, unlike serotonergic medications.

Saffron also acts on the serotonergic pathway: the combination is not dangerous at dietary doses but is redundant, and it is better to test one active ingredient at a time to know what works. With melatonin, the combination remains logically sound on paper—an upstream supply and the finished product—but no trial has evaluated it: start with one or the other.

Three hypotheses. The dose may have been too low compared to the trials; verify the amount of 5-HTP, not the extract weight. The problem may not be serotonergic: inflammatory fatigue, sleep apnea, iron deficiency, or a sluggish thyroid do not respond to 5-HTP. Or the intensity of the disorder exceeds what a supplement can accomplish, which is a reason to consult.

Anyone taking an antidepressant, tramadol, triptan, lithium, linezolid, or levodopa without medical advice, due to the risk of serotonin syndrome. Pregnant or breastfeeding women. Children, except by prescription. And people who already sleep well: trials show no effect in them.